FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL									
OMB Number:	3235-0287								
Estimated average burden									
hours nor reenense:	0.5								

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b)

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

						_													
1. Name and Address of Reporting Person* SCHEIBLER LUKAS						2. Issuer Name and Ticker or Trading Symbol Apellis Pharmaceuticals, Inc. [APLS]								5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner Officer (give title Other (specify					
	ELLIS PHA	irst) RMACEUTICA E, 3RD FLOOR	1		01/2	3. Date of Earliest Transaction (Month/Day/Year) 01/28/2021								X Officer (give title Other (specify below) CHIEF INNOVATION OFFICER					
(Street) WALTH			02451 (Zip)		4. If	4. If Amendment, Date of Original Filed (Month/Day/Year)								Individual or Joint/Group Filing (Check Applicable ne) X Form filed by One Reporting Person Form filed by More than One Reporting Person					
		Tab	ole I - Nor	n-Deriv	ative	Se	curities	s Ac	quired,	Dis	osed o	of, or Be	neficia	Ily Owned	<u> </u>				
1. Title of Security (Instr. 3) 2. Trans Date (Month/					action		2A. Deemed Execution Date, if any (Month/Day/Year)		3. Trans	Transaction Disposed Code (Instr. 5)		ities Acquir d Of (D) (In:	ed (A) or	5. Amou	s Formula (D) (O) (I) (I) (I)		n: Direct r Indirect istr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
					Code	v	Amount	(A) o (D)	r Price	Transac (Instr. 3	tion(s)			(111501.4)					
Common Stock 01/28						/2021		A ⁽¹⁾		7,500	7,500 A		28,	28,095(2)		D			
Common Stock 01/2					3/2021		A ⁽³⁾		1,875 A		\$(29	29,970		D				
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																		
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deeme Execution I if any (Month/Day	Date, 1	4. Transaction Code (Instr. 8)		ı of		6. Date Exercisal Expiration Date (Month/Day/Year			of Securi	g Security	Derivative Security	9. Numbe derivative Securities Beneficia Owned Following Reported Transactic (Instr. 4)	e s illy	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)	
					Code	v	(A)	(D)	Date Exercisal		xpiration ate	Title	Amount or Number of Shares						
Stock Option (Right to Buy)	\$44.9	01/28/2021			A		45,000		(4)	0	1/27/2031	Common Stock	45,000	\$0	45,000	0	D		
Stock Option (Right to Buy)	\$44.9	01/28/2021			A		11,250		(5)	0	1/27/2031	Common Stock	11,250	\$0	11,25	0	D		

Explanation of Responses:

- 1. This Restricted Stock Units grant will vest 25% annually over four years from grant date, subject to continued service.
- 2. Includes 482 shares from 4/30/20 ESPP Purchase and 321 shares from 11/30/20 ESPP purchase.
- 3. This Performance Unit grant will vest 25% annually over four years from grant date, subject to the satisfaction of a specified performance condition and continued service.
- 4. This stock option will vest as to 25% of the shares underlying the options on the first anniversary of the grant, with the remaining 75% of the shares underlying the options vesting in equal monthly installments thereafter through the fourth anniversary of the grant, subject to continued service.
- 5. This stock option will vest as to 25% of the shares underlying the options on the first anniversary of the grant, with the remaining 75% of the shares underlying the options vesting in equal monthly installments thereafter through the fourth anniversary of the grant, subject to the satisfaction of a specified performance condition and continued service.

/s/ David Watson, attorney-infact for Lukas Scheibler

01/29/2021 ** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.